// App-Quantinova.ai

T4186 2015 AHA : The Prognostic Value of Insulin-like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction: Results From Irbesartan in Heart Failure and Preserved Ejection Fraction (I-PRESERVE) Trial

Researchers

Presenter

  • Thomas S. Rector

Principal Investigators

  • Henry Krum

  • Hanna K Gaggin

  • John J McMurray

  • Michael Zile

  • Michel Komajda

  • Robert S. McKelvie

  • Peter E. Carson

  • James L Januzzi

  • Inder S. Anand

Medical Centers

  • APHP, Pitie-Salpetriere Hospital, paris, France

  • Massachusetts General Hospital, Boston, MA

  • McMaster University, Hamilton, ON, Canada

  • Western University of Health Sciences, Los Angeles, CA

  • Washington DC Veterans Affairs Medical Center, Washington, DC

  • Minneapolis VA Health Care System, Minneapolis, MN

  • Medcl Univ of South Carolina, Charleston, SC

  • University of Glasgow, Glasgow, United Kingdom

  • Deakin University, Melbourne, Australia

  • Parul U. Gandhi , Massachusetts General Hosp, Boston, MA

Locations

  • Canada

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Heart failure with preserved ejection fraction

  • Heart failure with reduced ejection fraction

Biomarkers

  • Angiomodulin

  • Nucleoside diphosphate kinase A

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Irbesartan

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved